Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CeriBell, Inc. - Common Stock (NQ:CBLL)

20.86 +0.25 (+1.24%)
Streaming Delayed Price Updated: 10:49 AM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CeriBell, Inc. - Common Stock

News headline image
AI Diagnostics: The End of the High-Cost Imaging Era
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the... 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Ceribell
Via GlobeNewswire
News headline image
Global AI Infrastructure Shift Ignites Biotech Growth Phase
From USA News Group
Via GlobeNewswire
News headline image
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Reports Third Quarter 2025 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025
From Ceribell
Via GlobeNewswire
News headline image
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Reports Second Quarter 2025 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Reports First Quarter 2025 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
From Ceribell
Via GlobeNewswire
News headline image
FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
Powered by Clarity, the Ceribell System will enable rapid, bedside detection, diagnosis and treatment of non-convulsive seizures in children experiencing neurological emergencies 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Reports Third Quarter 2024 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
From Ceribell
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.